Perioperative hypothermia usually results largely from pharmacologic inhibition of normal thermoregulatory control. Midazolam is a commonly used sedative and anesthetic adjuvant whose thermoregulatory effects are unknown.
Perioperative hypothermia usually results largely from pharmacologic inhibition of normal thermoregulatory control. Midazolam is a commonly used sedative and anesthetic adjuvant whose thermoregulatory effects are unknown.
We therefore tested the hypothesis that midazolam administration impairs thermoregulatory control. Eight volunteers were studied on 2 days each, once without drug and once at a target total plasma midazolam concentration of 0.3 pg/mL (corresponding to administration of -40 mg over -4 h). Each day, skin and core temperatures were increased sufficiently to provoke sweating, and then reduced to elicit peripheral vasoconstriction and shivering. We mathematically compensated for changes in skin temperature using the established linear cutaneous contributions to control of each response. From these calculated thresholds (core temperatures triggering responses at a designated skin temperature of 34"C), we determined the thermoregulatory effects of midazolam. The sweating threshold was decreased -0.3"C by midazolam administration: 37.3 ? 0.2"C vs 37.0 -C 0.3"C (P = 0.0004, paired t-test). Midazolam decreased the core temperature that triggered vasoconstriction somewhat more: 37.1 ? 0.2"C vs 36.3 ? 0.5"C (P = 0.0002). Similarly, midazolam decreased the shivering threshold: 35.9 t 0.3"C vs 35.3 + 0.6"C (P = 0.03). The sweating-to-vasoconstriction (interthreshold) range, therefore, increased from 0.2 -+ O.l"C to 0.7 t 0.3"C (P = 0.002). Although statistically significant, this relatively small increase contrasts markedly with the 3-5°C interthreshold ranges produced by clinical doses of volatile anesthetics, propofol, and opioids. Thus, plasma concentrations of midazolam far exceeding those used routinely produce relatively little impairment of thermoregulatory control.
( They were minimally clothed and rested supine in a 22-23°C room during the protocol. Studies were scheduled so that thermoregulatory responses were triggered at similar times each day.
A catheter was inserted in a left forearm vein for fluid and midazolam administration.
A 14-gauge catheter was inserted in a right antecubital vein for blood sampling.
Midazolam was administered using a pump programmed to target midazolam blood concentrations of 0.3 pg/mL using a modification of the method of and published data (16). This corresponded to infusion of -40 mg over the -4 h required for the protocol.
Airway support and ventilatory assistance was applied as appropriate for the degree of sedation. Ventilation was assisted when necessary to maintain normal end-tidal Pco, because hypercarbia may influence thermoregulatory responses (17). Oxygen was administered as necessary to maintain the hemoglobin oxygen saturation >95%.
Throughout the protocol, arms were protected from active warming and cooling to avoid locally mediated vasomotion (18). However, all other skin below the neck was similarly manipulated.
After 15 min of midazolam administration, skin and core temperatures were first gradually increased with a Bair Hugger@ forced-air warmer (Augustine Medical, Inc., Eden Prairie, MN) and circulating-water mattress (Cincinnati Sub-Zero, Cincinnati, OH) until significant sweating was achieved (19). Skin and core temperatures were then gradually decreased, using the circulatingwater mattress and a prototype forced-air cooler from Augustine Medical, Inc. (20) . This device provides 1000 L/min air at 14-15°C into a full-body disposable convective cover. The study ended each day when shivering was detected. Temperature changes were restricted to 13"C/h because this rate is unlikely to trigger dynamic thermoregulatory responses (1). Core temperature was recorded from the tympanic membrane using Mon-a-Therm@ thermocouples (Mallinckrodt Anesthesiology Products, Inc., St. Louis, MO). The aural probe was inserted by volunteers until they felt the thermocouple touch the tympanic membrane; appropriate placement was confirmed when volunteers easily detected a gentle rubbing of the attached wire. The aural canal was occluded with cotton, the probe securely taped in place, and a gauze bandage positioned over the external ear. There is an excellent correlation between tympanic membrane and distal esophageal temperatures in the perianesthetic period (2).
Mean skin-surface temperature and cutaneous heat transfer were calculated from measurements at 15 area-weighted sites (13,21). Temperatures were recorded at 1-min intervals from thermocouples connected to calibrated Iso-Thermex@ thermometers having an accuracy of O.l"C and a precision of O.Ol"C (Columbus Instruments, Corp., Columbus, OH). Sweating was quantified continuously on the left upper chest using a ventilated capsule (3,5). We considered a sustained sweating rate > 100 gm-2h' significant. Absolute right middle fingertip blood flow was quantified using venous-occlusion volume plethysmography at 5-min intervals (22). A sustained decrease in fingertip blood flow to CO.25 mL/min identified significant vasoconstriction (6). In previous similar studies, we used systemic oxygen consumption to quantify shivering (6). However, in preliminary studies we found that volunteers given midazolam to a total plasma concentration near 0.3 pg/mL move their extremities nearly constantly.
Because we were concerned that this background muscular activity might obscure the increase in oxygen consumption heralding onset of shivering, we instead evaluated shivering electromyographically.
After mild skin abrasion and degreasing, silver/silver chloride monitoring electrodes were positioned to record the electrical activity of the right pectoralis and trapezius, and the quadriceps bilaterally. The active electrodes were positioned 4 cm apart and oriented in the direction of the muscle fibers (23). After appropriate amplification, the signals were recorded on a thermoelectric printer having a linear resolution to 1000 Hz. Onset of shivering was subsequently determined by an investigator blinded to treatment and core temperature: sustained, synchronous waxing-and-waning activity identified significant shivering (24).
Peripheral venous blood was sampled at the time of sweating, vasoconstriction, and shivering for measurement of midazolam blood concentration.
To determine the fraction of unbound drug, 1 mL of fresh plasma from each sample was centrifuged using the Micro-partition System MIS-1 with YM-T membrane (Amicon, Inc., Denver, CO) for 30 min.
Plasma (500 pL) or ultrafiltrate (150-250 pL) were alkalinized with 100 PL 3 M NaOH and extracted into 4 mL ether, along with 25 PL 20-pg/mL diazepam as 1995;81:393-8 MIDAZOLAM MINIMALLY IMPAIRS THERMOREGULATION the internal standard, in a polypropylene centrifuge tube. The ether layer was transferred to a second polypropylene tube, evaporated to dryness under nitrogen at 4O"C, and reconstituted in a 200-PL mobile phase. The mobile phase was 30:70 acetonitrile:20 mM K,HPO, at pH 7.0, running through a 150-by 3.9-mm Novapak C, column (Waters Associates, Milford, MA) at 2 mL/min with detection by ultraviolet absorbance at 232 nm. The response is linear to at least 20 pg/mL, with a detection limit of 0.005 pg/mL with a 200-PL injection, and within-day coefficient of variation of 4.3% (n = 6), at 0.4 pg/mL. Heart rate and oxyhemoglobin saturation were measured continuously using pulse oximetry, and blood pressure was determined oscillometrically at 5-min intervals at the left ankle. End-tidal Pco, was measured from a catheter inserted into one nostril.
Hemodynamic responses, end-tidal Pcoz, and ambient temperature and humidity on each study day were first averaged within each volunteer; the resulting values were then averaged among volunteers. Results for each study day were compared using twotailed, paired t-tests. Total plasma midazolam concentrations and the unbound fraction at the sweating, vasoconstriction, and shivering thresholds were compared using repeated-measures analysis of variance and Scheffe's F-tests.
The cutaneous contribution to sweating (25) and to vasoconstriction and shivering (14) is linear. We thus used measured skin and core temperatures in degrees centigrade at each threshold to calculate the coretemperature threshold that would have been observed had skin been maintained at a single designated temperature:
where the fractional contribution of mean skin temperature to the threshold was termed /3. Tcore(calculated) thus equals the measured core temperature, T,,,,, plus a small correction factor consisting of p/(1 -p) multiplied by the difference between actual (Tskin) and designated [Tskin(designated)] skin temperatures. We have previously described the derivation and validation of this equation (6). We used a /3 of 0.1 for sweating (25) and a p of 0.2 for vasoconstriction and shivering (14). The designated skin temperature was set at 34"C, a typical intraoperative value. Response thresholds, the interthreshold range, and the vasoconstriction-to-shivering range were compared using two-tailed, paired t-tests. All results are presented as mean +-SD, P < 0.05 was considered statistically significant. 
Results
Volunteers typically were deeply sedated during midazolam administration and typically were unresponsive to verbal stimulation. Ambient temperatures and relative humidity were comparable on each of the study days. Heart rates, blood pressures, and end-tidal Pco, also were similar (Table 1) . Total plasma midazolam concentrations were similar at the sweating, vasoconstriction, and shivering thresholds. Approximately 6% of the plasma midazolam was in its unbound, active form ( Table 2) .
The sweating threshold was decreased -0.3"C by midazolam administration: 37.3 +-0.2"C vs 37.0 +-0.3"C (P = 0.0004). Midazolam decreased the core temperature triggering vasoconstriction somewhat more: 37.1 + 0.2"C vs 36.3 ? 0.5"C (P = 0.0002). Similarly, midazolam decreased the shivering threshold: 35.9 + 0.3"C vs 35.3 -t 0.6"C (P = 0.03).
As a result, the interthreshold range increased from 0.2 + O.l"C to 0.7 + 0.3"C (P = 0.002). In contrast, the vasoconstriction-to-shivering range did not increase significantly: 1.1 t 0.3"C vs 1.0 ? 0.5"C (Table 3 , Fig. 1 ).
Discussion
The plasma concentration of midazolam at which 50% of the subjects respond to verbal command is -0.6 pg/mL in 40-yr-old subjects (26). The plasma midazolam concentration targeted in this study was less, but similar to that measured in critical care patients given long-term infusions of the drug at comparable rates (27). It far exceeded concentrations likely after relatively small doses used for premeditation or sedation. Such doses, presumably, produce even less thermoregulatory impairment than observed in our volunteers.
Midazolam slightly decreased the sweating threshold, but decreased the vasoconstriction threshold somewhat more. Although the interthreshold range tripled, it was only 0.7"C after this large dose of midazolam. This value is considerably less than the 3-5°C interthreshold range produced by clinically relevant levels of enflurane (4,5), isoflurane (2,3), and propofol (6). It is similar to the interthreshold range during spinal and epidural anesthesia (28). The shivering threshold was somewhat reduced by midazolam administration. However, vasoconstriction and shivering thresholds decreased comparably so the vasoconstriction-to-shivering range remained normal throughout the study.
In distinct contrast to low-dose propofol (7) and opioids (unpublished data), midazolam does not produce substantial inhibition of thermoregulation.
Thus midazolam is the first tested major sedative/ anesthetic showing little thermoregulatory effect in humans. These data suggest that patients premedicated or sedated with midazolam will maintain nearly normal core temperatures in typical hospital environments until induction of anesthesia. Conversely, midazolam is unlikely to prove an effective treatment for postoperative shivering (23) and would not facilitate induction of deliberate hypothermia by inhibiting thermoregulatory vasoconstriction (20) .
Midazolam produced relatively little thermoregulatory impairment, but the pattern of threshold changes was novel: not only were the cold-response thresholds reduced, but the sweating threshold was as well. Reduction in the sweating threshold contrasts markedly with previously tested sedatives and anesthetics. Lower sweating and vasoconstriction thresholds most likely correspond to a reduction of the "set point" (set point refers to the sweating and vasoconstriction thresholds-ignoring the normally small difference between them). An alternative, but less likely, possibility is that midazolam simultaneously reduces both thresholds via peripheral mechanisms. Commonly used antipyretic medications reduce the febrile set point by blocking the central effect of endogenous pyrogens (29). However, aspirin reduces coldresponse thresholds even in the absence of fever (30,311. Midazolam possibly acts similarly, although it seems unlikely to posses direct antipyretic properties.
Just how the normal set point is established is poorly understood, although the model proposed by Hammel (32) in 1965 remains well regarded. Hammel suggests that warm-sensitive neurons and temperature-insensitive neurons send separate, mutually antagonistic synaptic inputs to thermoregulatory effector neurons. Recent studies support the general outline of this model, and further suggest that inhibition of warm-sensitive neurons by inhibitory postsynaptic potentials is a key factor influencing firing rate (33). Most likely, midazolam (in sufficient concentrations) directly impairs some aspect of normal set point control, resulting in a combined reduction of the set point and increase in the interthreshold range. MIDAZOLAM MINIMALLY IMPAIRS THERMOREGULATION In previous thermoregulatory studies, we evaluated concentration-response relationships. However, preliminary studies with midazolam indicated that the drug produced only minimal thermoregulatory impairment. We thus tested only a single plasma concentration, but one at the highest end of the clinically relevant range. Our results thus provide an upper limit on the thermoregulatory effect that might be expected in routine practice. In the absence of additional data, we have no assurance that the thermoregulatory effects of midazolam are a linear function of plasma concentration.
But the relationship is nonetheless likely to be linear, since for all drugs so far tested, inhibition of thermoregulatory control is in direct proportion to end-tidal or plasma concentration (2-6). Thermoregulatory responses are not only characterized by thresholds, but also by gain (the rate at which response intensity increases as temperature deviates from threshold) and maximum response intensity (greatest possible response intensity) (34). Gain and maximum response intensity of sweating are not reduced by enflurane (5) or isoflurane (3). Isoflurane does not reduce the maximum intensity of arteriovenous shunt vasoconstriction (35) . In this study, we evaluated only thresholds. Although it is possible that gain or maximum intensity might be significantly impaired, it seems unlikely that either is reduced sufficiently to alter our primary conclusion that clinical doses of midazolam minimally impair thermoregulatory control.
In summary, plasma concentrations of midazolam near 0.3 pg/mL increased the interthreshold range from 0.2 2 O.l"C to 0.7 ? 0.3"C. This small increase contrasts markedly with the 3-5°C interthreshold ranges produced by clinical doses of volatile anesthetics, propofol, and alfentanil. 
